

1 **Erythrovirus B19 (B19V) in patients with acute febrile illness**
2 **suspected of arboviruses in Mato Grosso do Sul, Brazil**

3 Gislene Garcia C. Lichs^{1,5}, Zoraida del Carmen Fernandez Grillo², Valdinete Alves do
4 Nascimento³, Daniel Maximo Corrêa Alcantara², Everton Ferreira Lemos⁴, Cristiano M.
5 Espínola Carvalho⁶, Luiz Henrique Ferraz Demarchi¹, Crhistine Carvalho Maymone
6 Gonçalves^{5,7}, Felipe Gomes Naveca^{3,8}, Alexsandra Rodrigues de Mendonça Favacho^{2,5}

- 7 1. Laboratório Central de Saúde Pública de Mato Grosso do Sul, SES-MS, Campo Grande, Brazil;
8 2. Fundação Oswaldo Cruz, Fiocruz Mato Grosso do Sul, Campo Grande, Brazil;
9 3. Núcleo de Vigilância de Vírus Emergentes, Reemergentes ou Negligenciados, Instituto Leônidas e Maria Deane, Fiocruz,
10 Manaus, Amazonas, Brazil;
11 4. Universidade Estadual de Mato Grosso do Sul - UEMS, Campo Grande, Brazil;
12 5. Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil;
13 6. Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul, Brazil;
14 7. Secretaria de Estado de Saúde de Mato Grosso do Sul, Campo Grande, Brazil;
15 8. Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.

16 Corresponding author: Gislene Lichs (glichs@hotmail.com)

17 Abstract

18 Human Erythrovirus (parvovirus) B19 infection can produce symptoms similar to those
19 produced by Dengue, Chikungunya, and Zika viruses, making clinical diagnosis difficult. The
20 importance of erythrovirus B19 in human pathology has been increased and reported in
21 numerous studies published globally. The B19V infection was investigated by real-time PCR
22 in samples from patients with signs and symptoms related to classic arboviral symptoms. This
23 study was conducted to provide information on the genetic diversity of Human Erythrovirus
24 B19 (B19V) circulating in the state of Mato Grosso do Sul, Midwest region of Brazil, from
25 2017 to 2022. A total of 773 sera samples of patients with negative diagnostic results for
26 Dengue, Chikungunya, and Zika, during the study period were analyzed. Erythrovirus DNA
27 was found in 10.6% (82/773) of patients, among them 10 were pregnant women. Four
28 samples were completely sequenced, and the other five partially, to genotype by phylogenetic
29 reconstruction. All samples belong to worldwide dispersed genotype 1, subgenotype 1a.
30 These results demonstrate the importance of including B19V in differential laboratory
31 diagnosis for epidemiological purposes and appropriate patient management. The diagnosis
32 for B19V should be performed, particularly among pregnant women, immunocompromised
33 patients, and individuals with hemolytic diseases, as the infection is more severe in these
34 cases.

35 Introduction

36 Human Erythrovirus B19 (parvovirus B19), of the *Parvoviridae* family, a member of the
37 *Erythroparvovirus* genus, was discovered in England by Yvonne Cossart et al in 1975 [1] in
38 serum samples from blood donors who performed serological testing for hepatitis B virus.
39 This sample was coded as "number 19 in panel B", and later the virus was called B19 [1].
40 After its discovery, the B19V infection was associated with an asymptomatic or benign acute
41 pediatric infection known as erythema infectiosum and other clinical manifestations such as
42 transient aplastic crisis, and arthropathies [2].

43 The transmission of B19V is through the respiratory droplets. However, the virus can also be
44 transmitted parenterally, especially by haemoderivative applications [3]. The Erythrovirus
45 B19 has a tropism for human erythroid progenitor cells and it is involved in suppressing
46 blood cell formation during infection [4]. In 2002, the virus was classified into three
47 genotypes, defined as genotype 1 B19 classic (represented by the prototype strain Au),
48 genotype 2 (prototype K71 and strain A6-similar), and genotype 3 (prototype V9) [5].

49 The infection by Human Erythrovirus B19 during pregnancy has been widely studied, and it
50 is known to cause a range of complications, including spontaneous abortion [2]. The virus
51 acts on the inhibition of red blood cell formation, generating cytotoxic effects that lead to
52 variable clinical conditions, such as intrauterine growth retardation, myocarditis, and
53 pericardial effusions, which will depend on the patient's hematological and immunological
54 status. The age group most affected is children/adolescents under 14 years old [6]. However,
55 many infections are asymptomatic and are not correctly diagnosed.

56 In Brazil, the B19V and some arboviruses (Dengue, Chikungunya, and Zika) co-circulate in
57 several regions of the country, making the differential diagnosis difficult, mainly because
58 these viruses can cause similar symptoms associated with exanthema and acute febrile
59 diseases [7].

60 The disease caused by B19V was not classified as national or state compulsory notification,
61 in Brazil. The infection was detected in surveillance of exanthematous diseases, as a
62 differential diagnosis in suspected cases of measles or rubella, according to the characteristics
63 of symptoms [8]. In 2020, in a meeting between the State Secretary of Health of Mato Grosso
64 do Sul (SES) and the Central Laboratory of Public Health (LACEN) it was agreed that
65 suspected cases of Erythema Infectiosum (B19V) should be notified, but it was only from
66 2021 that some cases were included in the Notification Diseases Information System
67 (SINAN). The detection of IgM antibodies against parvovirus B19 is carried out at the
68 LACEN following national guidelines and protocols provided by the Ministry of Health.
69 Diagnosis for B19V, using real-time PCR, should be performed particularly among pregnant
70 women, immunocompromised patients, and individuals with hemolytic diseases since the
71 infection is more serious in these cases. The implementation in the laboratory routine can
72 clarify whether erythrovirus B19 may be one of the etiological agents of exanthematous
73 diseases, as well as determine the frequency of their infection in patients.

74 The current study aims to evaluate the presence of Human Erythrovirus B19 in samples from
75 patients with negative diagnostic results for Dengue, Chikungunya, and Zika collected in
76 several municipalities in the state of Mato Grosso do Sul, Brazil, from 2017 to 2022, and
77 provide information of molecular characterization and genetic variability of circulating
78 strains of Human Erythrovirus B19 in the state.

79

80 **Materials and Methods**

81 **Study design and sampling**

82 Biological samples were selected from the Biobank of the Central Laboratory of Public
83 Health of Mato Grosso do Sul state (LACEN/MS), based on the following criteria: (i) serum,
84 urine, and cerebrospinal fluid samples collected between January 2017 and October 2022; (ii)
85 with clinical suspicion of chikungunya, dengue or zika disease but with negative test results
86 (“not detectable” by the RT-qPCR and “non-reactive” when using the NS1 and enzyme-
87 linked immunosorbent assay (ELISA) for these arboviruses; (iii) reported onset of symptoms
88 within 5 days for the NS1 test; and (iv) availability at the time of sample selection, since a
89 substantial number of samples were discarded during the laboratory routine due to a lack of
90 storage capacity, a condition exacerbated by the SARS-CoV-2 pandemic; v) samples with a
91 volume equal or more than 200 microliters.

92 Socio-demographic and clinical data of each sample were obtained from the medical request
93 forms to assess associations with Erythrovirus B19 infection, including, gender, age, city of
94 residence, reported symptoms, pregnancy, and confirmation of death. In addition, the records
95 of positive cases of CHIKV, DENV, and ZIKV during the routine diagnosis of LACEN/MS
96 were compared with the qPCR results obtained for B19V in the present study.

97 **Ethical Approval**

98 This study was conducted with the authorization of the Human Research Ethical Committee
99 of the Dom Bosco Catholic University of Mato Grosso do Sul, Brazil
100 (CAAE:54019821.2.0000.5162).

101 **Virus detection**

102 The nucleic acids of each sample were extracted using the QIAasympyphony
103 DSPVirus/Pathogen Mini Kit (QIAGEN), according to the manufacturer's protocol. The
104 extracted DNA was tested for B19V using the protocol developed by Naveca et al. (data not
105 yet published) from the Leônidas and Maria Deane Institute (ILMD), Fiocruz Amazônia.
106 Primers and probes are presented in Table S1. Real-time PCR (qPCR) was performed using
107 the KAPA PROBE FAST qPCR Master Mix (2X) (Roche), following the calculations shown
108 in Table S2. In all the reactions, the amplification of the human internal control gene (RNase
109 P) was used to rule out false negatives, thereby confirming the accuracy of the results. A no-
110 template control and positive control for B19V were used to discard possible contamination
111 and validate the reaction. The qPCR was performed using the ABI 7500 and QuantStudio™ 5
112 (Applied Biosystems). Following the manufacturer's protocol, it applied an initial
113 denaturation at 95°C for 5', with 40 cycles of denaturation at 95°C for 3" and combined
114 annealing/extension/data acquisition at 60°C for 30". The threshold for the quantification
115 cycle (Cq) was calculated automatically with default settings using equipment software. The
116 results were considered "positive" for B19V when the Cq value was ≤ 37 .

117 **Sequencing**

118 Samples with positive results for B19V were amplified by conventional PCR using three
119 pairs of primers (Table S3), covering almost the entire viral genome. Nine samples were
120 separated for sequencing (Table 2). They were indicative of the first three years of the study
121 and also had a high viral load. PCR reactions were performed using SuperFi II green enzyme
122 (Thermo Fisher Scientific), primers at 0.5 μ M, and 1 μ L of viral DNA in 10 μ L of the final
123 volume. The recommended cycling parameters were as follows, 98°C of initial denaturation
124 for 30", 35 cycles of 10" denaturation at 98°C, 10" annealing at 55°C, 2' extension at 72°C,
125 ending with 5' final extension at 72°C.

126 At the end of the reactions, each amplicon was subjected to electrophoresis at 80V for 1 h,
127 visualized on a 1% agarose gel stained with GelRed (Biotium), and the GeneRuler 1 kb DNA
128 Ladder (Thermo Fisher Scientific) was used to confirm the expected size of the product.
129 Subsequently, the PCR products were precipitated using polyethylene glycol 8000 following
130 an adapted protocol. Initially, 20% PEG8000 (Promega) was added at a 1:1 ratio to the tube
131 containing the PCR product, followed by incubation at 37°C for 15 min. After incubation,
132 centrifugation was performed at 13,000 \times g for 15 min. The supernatant was then discarded,
133 125 μ L of 80% ethanol was added, followed by a new centrifugation step at 12,000 \times g for 2
134 min, and the supernatant was discarded. The microtube was then placed in a Mivac DNA
135 concentrator (Genevc SP Scientific) for 15 min at 37°C. DNA was then resuspended in
136 nuclease-free water and quantified using a microvolume spectrophotometer (Biodrop Duo
137 Biochrom). All amplicons from the same sample were pooled together and quantified using
138 the Qubit 2.0 and dsDNA HS Assay kit (Thermo Fisher Scientific).

139 Four samples were suitable for whole-genome sequencing. Library preparation was
140 performed using a Nextera XT DNA Library Prep Kit (Illumina). Enzymatic tagmentation,
141 adapter, and index addition, amplification, normalization, and pool libraries were performed
142 as described in the manufacturer's manual using 1ng of DNA. All libraries were quantified
143 using a Qubit dsDNA HS Assay Kit. Sequencing was performed on MiSeq equipment
144 (Illumina) using the Reagent v2 500-cycle sequencing kit. The data generated after
145 sequencing were analyzed in Geneious Prime 2022.0.1 software for the assembly of contigs

146 of each sample, using the genome NC_000883 as the reference and the BMAP v 38.84 tool
147 under "default" conditions. The remaining five samples were partially sequenced (ranging
148 from 585 to 1281 base pairs of the VP1/VP2 gene) using standard procedures for capillary
149 sequencing, as recommended for ABI3130 (ThermoFisher). Trace files were edited for
150 quality and primer removal and assembled using the B19V. The nucleotide sequences
151 obtained during this study were deposited in the GenBank database (Table 2).

152 **Phylogenetic analysis**

153 The consensus B19V sequences obtained in this study and the reference sequences available
154 on GenBank [G1a: M13178 (isolated Au); G1b: DQ357064 (isolated Vn147); G2:
155 AY064475 (isolated A6); G2 AY044266 (isolated LaLi); G3a: AX003421 (isolated V9) and
156 G3b: AY083234 (isolated D91.1)] were aligned using the MAFFT v7.490 tool with
157 automatic algorithm selection. Subsequently, the alignment file was subjected to maximum-
158 likelihood phylogenetic reconstruction with the FastTree 2.1.11 program using the GTR
159 evolutionary model. An approximate likelihood ratio test (aLRT) [9] was used to assess the
160 branch supports. The phylogenetic tree had the root placed at the central point, with
161 increasing node order, and was edited in the FigTree 1.4.4 program. Tip labels were aligned
162 for clarity.

163 **Statistical analyses**

164 Mixed Generalized Linear Models (GLMMs) with random effects for municipalities and
165 binomial distribution were used to understand how PCR test results could be related to (1) the
166 age and gender of patients, as well as the year of sampling; and (2) the symptoms recorded in
167 patient records. Symptoms were evaluated in a separate model, owing to fewer records.
168 Multicollinearity was checked by examining the Pearson correlation coefficient (Pearson's r)
169 between each pair of explanatory variables, using the R package 'correlation' [10], and
170 computing the variance inflation factor (VIF), with the R package 'performance' [11]. The
171 analyses were performed using the 'lme4' package [12] in the R software [13]. Tables and
172 estimation plots were generated using the 'jtools' package [14]. The models were checked for
173 normality of residuals, normality of random effects, homogeneity of variance, and residual
174 dispersion using the packages 'DHARMA' [15] and 'performance'.

175 In years when sampling was conducted for all months, circular statistics were employed to
176 test seasonal patterns in the number of cases in Mato Grosso do Sul [16-18]. Two approaches
177 were used: (1) a hypothesis test and (2) a model-based approach, both implemented in the R
178 package 'CircMLE' [19]. In the hypothesis test, the null hypothesis is that the data are
179 uniformly distributed throughout the year, versus some form of concentration, be it unimodal,
180 bimodal, or multimodal [18]. The Hermans-Rasson test was used to verify the uniformity of
181 the distributions, as it has high statistical power for grouped multimodal distributions [17]. In
182 the model-based approach, the package calculates the maximum likelihood of 10 models
183 described by [20] and compares them using model selection criteria. Thus, this approach
184 allows the identification of patterns of occurrence. Briefly, the models fall into three main
185 categories: (i) a uniform model (M1) of random orientation; (ii) unimodal models (M2A,
186 M2B, M2C) with a single preferred direction; and (iii) bimodal models (M3, M4, and M5)
187 with two preferred directions. Bimodal models can also be divided into axial (M3A, M3B,
188 M4A, M4B) and non-axial (M5A, M5B) [18-21]. Herein, the models were compared based
189 on Akaike's Information Criterion with small-sample correction (AICc). Additionally, the
190 Akaike weight (w_i) was used, which describes the probability that a particular model is the

191 best model (approximate), given the experimental data and the collection of models
192 considered [21-23]. For each year, it was also calculated the circular standard deviation (sd),
193 circular mean (μ), and the length of the mean vector (r) using the R package ‘circular’ [24].
194 The μ represents the mean date of cases, and r represents how the data is clustered around the
195 mean (0, perfectly uniformly distributed; and 1, perfectly clustered). All statistical analyses
196 were performed using the R software v4.2.1.

197 RESULTS

198 Between January 2017 and October 2022, LACEN/MS performed 26,154 tests for at least
199 one of the three arboviruses. Some of the samples received for diagnosis of dengue were also
200 tested for CHIKV and/or ZIKV, and others were just evaluated for CHIKV and/or ZIKV. Of
201 the total samples analyzed, 7,239 were tested for CHIKV, 14,247 for DENV, and 4,668 for
202 ZIKV. Of those, 7,162 were negative for CHIKV (98.9%), 7,340 for DENV (51.5%), and
203 4,634 for ZIKV (99.3%) (Figure 1). Despite the high number of tests performed, few samples
204 were available at the time of sample selection. Therefore, only 773 samples from 62
205 municipalities in the state of Mato Grosso do Sul met the previously defined criteria, had
206 negative results for dengue, zika, and chikungunya, and were chosen for B19V research
207 (Figure 1). Of the total samples analyzed, 82 were positive for B19V (10.6%), from 24
208 municipalities (Table 1; Figure 2), surpassing the number of cases registered for
209 Chikungunya and Zika during the same period in the state of Mato Grosso do Sul (Figure 3).

210 Of the total positive samples, 28 were collected in men and 54 in women (Figure S1), with 10
211 pregnant women. The ages of patients ranged from 1 to 70 years, however, B19V detection
212 was not significantly associated with gender and age group, although it was significantly
213 different between the years of the period evaluated (Figure 4A). The positive results in the
214 years 2019, 2021, and 2022 were significantly lower than in 2017 (Table 1; Figure 4A). The
215 notification forms of 598 patients contained clinical information, identifying a total of 20
216 symptoms. Among B19V-positive patients, fever was the most frequent symptom, followed
217 by myalgia, headache, arthralgia, retro-orbital pain, nausea, and rash. (Figure 5). Despite this,
218 B19V detection was significantly associated only with retro-orbital pain, leukopenia,
219 petechiae, and malaise (Table 1; Figure 4B). The symptom “abdominal discomfort” was not
220 included in the model because it was correlated with “diarrhea”. The symptoms “gingival
221 bleeding”, “renal failure”, “sore throat” and “thrombocytopenia” were not included because
222 they only had 2 cases in the notification forms, causing problems in the estimates.

223 The phylogenetic reconstruction showed that all samples sequenced in this study were
224 recovered with Genotype 1, subgenotype 1a (RefSeq M13178), with high support (aLRT =
225 0.94) (Figure 6). The B19V samples that underwent sequencing originate from different
226 municipalities (Corumbá, Campo Grande, Dourados, Deodópolis, Caarapó, Chapadão do Sul,
227 and Alcínópolis) in various geographic areas, demonstrating the wide spread of the virus by
228 the whole state. Identifiers (CodeID) were created for each sample to ensure the
229 confidentiality of the subjects' identities in the study and to prevent recognition by anyone
230 outside the research group (Table 2; Figure S2).

231 The results of the Hermans-Rasson test demonstrated that the number of cases was seasonal
232 for all the years evaluated, 2017 (7.29; $p = 0.033$), 2018 (13.02; $p < 0.001$), and 2019 (13.90;
233 $p < 0.001$). For 2017, despite the best model having presented an AICc w_i with more than
234 twice the second, the following models can still be considered plausible choices. When
235 considering the first two models (M3A and M4A, AICc $w_i = 0.38$ and 0.17; Figure 7; Table

236 S4), they together presented an AICc $w_i = 0.55$, which means that there is at least a 55%
237 chance that it is the best approximation that describes the data, given the candidate set of
238 orientations considered. Both models are axial bimodal, suggesting a distribution in two
239 equally sized points in 2017, one in each semester, with the mean date of cases in September
240 (mean date = September 01, 2017; sd = 1.67; $r = 0.25$). In 2018, no model stood out, and the
241 first two were equally supported, with close AICc w_i values, which, together, presented a
242 value of AICc $w_i = 0.71$ (M5A and M3A, AICc $w_i = 0.38$ and 0.33 ; Figure 7; Table S5).
243 Although both have a bimodal distribution, one is non-axial (M5A), while the other is
244 (M3A), making it more complicated to determine a pattern for the year 2018. Even so, both
245 models showed a division of distribution between the two semesters, with a greater presence
246 of cases closer to the end of each semester, with the mean date of cases in July (mean date =
247 July 23, 2018; sd = 1.68; $r = 0.25$). In contrast, the pattern shown in 2019 was unequivocal,
248 with an unimodal distribution (M2A, AICc $w_i = 0.72$; Figure 7; Table S6) concentrated in the
249 first half, with the average date in March (mean date = March 17, 2019; sd = 1.03; $r = 0.59$).

250 **DISCUSSION**

251 A wide variety of viruses can cause rashes and joint pain in children, adolescents, and adults,
252 leading to etiological identification exclusively through clinical examination, which makes it
253 a challenging task. The most common agents of exanthematous disease (ED) include
254 Measles, Rubella, Dengue, Chickenpox, Cytomegalovirus, Epstein Barr, Human HerpesVirus
255 6, Enterovirus, Erythrovirus (Human Parvovirus B19), Chikungunya and Zika [25]. Although
256 these injuries are common in Brazil, there are several difficulties in determining an accurate
257 etiological diagnosis, especially in those regions where there is co-circulation of
258 exanthematous diseases. Therefore, the differential diagnosis of these diseases is extremely
259 important, not only for epidemiological purposes but also for the control and treatment of
260 infections. Even if most of them have a benign course, for certain age groups, pregnant
261 women, and immunocompromised people, some infections represent an important risk, as
262 they can evolve into serious cases, which may require emergency hospitalization, burdening
263 the public health service [6].

264 Molecular diagnosis of B19V infection is not commonly used as a differential diagnosis, and
265 there are no studies dealing with the detection of B19V using the qPCR methodology in the
266 state of Mato Grosso do Sul, Brazil. The continuous lack of specific studies for B19V in the
267 state of Mato Grosso do Sul may be contributing to the high number of cases that are not
268 laboratory-confirmed (Figure 3). This highlights the need to expand laboratory diagnosis so
269 that B19V can be monitored. However, it is important to point out that the use of a sensitive
270 and specific molecular method is of paramount importance for clarifying the laboratory
271 diagnosis of different viral infections. Thus, our study is the first one showing the circulation
272 of B19V in the state of Mato Grosso do Sul, in the Midwest region of Brazil, using the new
273 protocol developed by F.G. Naveca and his team. Also, our study demonstrates the need and
274 feasibility of implementing B19V detection as a differential diagnosis in patients with acute
275 febrile illness or suspicion of arbovirus infection.

276 Erythrovirus B19 can occur in individuals of all age groups and from different population
277 groups [26], which is supported by our results (Figure 4A). The B19V infection is usually
278 characterized as acute and self-limited, but clinical manifestations might vary according to
279 the immunological and hematological profile of each person [26]. Some studies describe
280 arthralgia as the most characteristic symptom of B19V infection, especially in adults [27, 28].
281 Herein, the most common symptoms recorded were, in decreasing order of frequency, fever,

282 myalgia, headache, and, only then, arthralgia (Figure 5). Also, the detection of B19V was
283 significantly associated with the symptoms of “retro-orbital pain”, “leukopenia”, “petechiae”
284 and “malaise” (Figure 4B), thus, diverging from previous studies. However, regardless of the
285 existence of symptoms that might be more associated with B19V infection, there is immense
286 difficulty in distinguishing it from other exanthematous diseases due to the similarity of
287 symptoms. The similarity of the symptoms of erythema infectiosum to other cutaneous
288 exanthematous diseases, together with the wide circulation of arboviruses in Brazil, make the
289 clinical diagnosis a difficult challenge to overcome [6]. In this sense, a study published by
290 [29] showed that about 19% of cases of exanthematous diseases remain without a
291 confirmatory diagnosis; among them, B19V infection is the major cause (33%). Hence, it is
292 essential to carry out a specific laboratory diagnosis for the correct identification of the
293 exanthematous disease agent.

294 In our study, ten pregnant women tested positive for B19V. Infection by B19V during
295 pregnancy is a serious public health problem, as abortion can occur in the first trimester of
296 pregnancy and in the second trimester, the fetus can develop non-immune hydrops fetalis
297 [30]. The infection can result in vertical transmission to the fetus, causing infection of
298 erythroid precursors and intense hemolysis, leading to severe anemia, fetal hydrops, and
299 death. Rapid correction of anemia by transfusion of packed red blood cells in utero largely
300 prevents fetal death [31]. Unfortunately, it was not possible to track the positive pregnant
301 women to verify the outcome of each case, since they were not diagnosed promptly for
302 adequate follow-up during pregnancy. Women of reproductive age have an annual
303 seroconversion rate of 1.5%, and as in the population group of pregnant women the disease
304 tends to be more severe, so the pregnancy must be monitored medically with the detection of
305 B19V [32].

306 The identification of B19V “Genotype 1a” (Figure 6) demonstrates the importance of
307 differential laboratory diagnosis using molecular techniques in patients with fever and
308 characteristic symptoms, to assist the health surveillance system through continuous
309 monitoring to detect all circulating genotypes and the spread of the virus in the population.
310 There are three recognized genotypes of B19V (1, 2, and 3), segregated into subtypes 1a, 1b,
311 2, 3a, and 3b [4, 33-35]. All three genotypes have been reported in both symptomatic and
312 asymptomatic persons, and no association has been established between genotype and clinical
313 manifestations [36-41]. Genotype 1 is the most prevalent in the world. In Brazil, the three
314 genotypes have already been detected, but there is also a predominance of Genotype 1 [42,
315 43]. The first complete genome of B19V genotype 1 a was from a serum sample suspected of
316 dengue infection, from a fatal case of a 12-year-old boy in Rio de Janeiro, Brazil [35]. The
317 viral genome of erythrovirus B19 is highly conserved, with 98-99% similarity between
318 isolates [44, 45], which means that a few sequenced samples are enough to know the
319 circulating genotype.

320 An important characteristic of B19V infection in Brazil is its cyclic pattern of occurrence
321 every 3 to 5 years, observing years with high infection rates followed by periods with low
322 circulation, as occurred in 1988-1989, 1995-1996, 1999- 2000, 2004-2005, 2009-2010, 2013-
323 2014 [46, 47]. Our results corroborate these previous studies, suggesting that B19V has a
324 cyclical pattern of occurrence in Mato Grosso do Sul (Figure 7). There was a greater number
325 of cases in 2017 and 2018, having decreased in 2019, rising again in 2020, and decreasing
326 again in 2021 and 2022, with a positivity percentage of 20.7%, 13.75%, 8.8 %, 18.3%, 2.3%
327 and 3.4% respectively (Table 1; Figures 3 and 4A). However, further studies are needed over
328 a longer period, since the cycle can last from 4 to 5 years [46]. Additionally, as three years of

329 the study overlapped with the COVID-19 pandemic, this may also have influenced the
330 dynamics of circulation and transmission of B19V.

331 CONCLUSION

332 Timely information represents an essential tool for epidemiological surveillance, as it triggers
333 the “information-decision-action” process, a triad that summarizes the dynamics of its
334 activities, which, as is known, must be initiated from the information of an indication or
335 suspected case of any disease or injury. Although not a new concern, our study demonstrates
336 the importance of the differential diagnosis of B19V in the population, with main attention to
337 pregnant women. As an example, clinical and epidemiological studies carried out in the
338 North region, in 1993, already showed that B19V was becoming a public health problem on
339 the rise at that time [48]. Our study population did not have a laboratory-confirmed diagnosis
340 and, therefore, surveillance did not carry out control actions. This evidences the need for
341 investment in the implementation of methodologies that maintain a high sensitivity of viral
342 detection in areas at risk of emergence of emerging and reemerging pathogens. By identifying
343 the agent that is affecting the population, medical conduct and epidemiological surveillance
344 actions will be better directed. Further, continuous monitoring is needed to detect all known
345 genotypes and the emergence of new genotypes for the control of cases.

346 TABLES

347 **Table 1:** Population and municipalities studied by year and positive cases for B19V.

Year	Samples	Positives (%)	Municipalities sampled	Municipalities with positive cases (%)
2017	82	17 (20.7)	28	10 (35.7)
2018	160	22 (13.8)	27	10 (37.0)
2019	285	25 (8.8)	39	11 (28.2)
2020	71	13 (18.3)	22	6 (27.3)
2021	86	2 (2.3)	15	1 (6.7)
2022	89	3 (3.4)	22	3 (13.6)
Total	773	82 (10.6)	62	24 (38.7)

348

349 **Table 2:** Characteristics of samples sequenced to identify the circulating B19V genotype. All municipalities are in the state of Mato Grosso do Sul,
 350 Brazil. The GenBank access numbers are shown for each sample.


Code ID	Gender	Municipality	Collection date	Pregnancy	Accession number
MS-B19-17-201-532	Woman	Dourados	03/2017	Yes	OR542579
MS-B19-17-32-174	Woman	Chapadão do Sul	05/2017	No	OR542583
MS-B19-17-25-839	Woman	Corumbá	05/2017	Yes	OR542582
MS-B19-17-201-1400	Woman	Dourados	07/2017	Yes	OR578525
MS-B19-17-18-408	Woman	Caarapó	08/2017	No	OR542580
MS-B19-17-31-100	Woman	Eldorado	10/2017	No	OR578526
MS-B19-17-31-148	Man	Eldorado	11/2017	-	OR578523
MS-B19-18-102-7397	Man	Campo Grande	07/2018	-	OR578524
MS-B19-19-04-3	Woman	Alcinópolis	01/2019	No	OR542581

351 -,

not

applicable.

352 **FIGURES**




353


354 **Figure 1.** Flowchart of the experimental design of the present study.

355

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .




356
357 **Figure 2.** Positive cases of B19V, according to municipalities in the state of Mato Grosso do
358 Sul, during the period from 2017 to 2022.



359

360 **Figure 3.** Samples of arboviruses surveyed at LACEN/MS and their results compared to
 361 B19V, from 2017 to 2022. The bar graph shows the proportion of molecular test results for
 362 all arboviruses examined in LACEN/MS. The lines indicate the percentage of positive results
 363 for each virus.


364



365


366 **Figure 4.** Estimates of mixed generalized linear models. (A) Estimates of patient
 367 characteristics and period. (B) Estimates of symptoms. Filled dots indicate significant
 368 variables ($p < 0.05$); bars represent the 95% confidence interval; β , estimate; numbers in
 369 parentheses indicate the estimated 95% confidence intervals; p , p-value.

370



371

372 **Figure 5.** Frequency of symptoms by age group of the studied population.




373

374 **Figure 6.** Phylogenetic relationship of sequenced samples and B19V genotypes (1a, 1b, 2, 3a
 375 and 3b). The samples sequenced in this study start with “MS-B19”. The reference sequences

376 obtained from GenBank are identified by their accession number. The numbers above
377 branches indicate the approximate likelihood ratio test (aLRT).

378



379

380 **Figure 7.** Circular histograms of several B19 cases per month for the years 2017, 2018, and
381 2019. In the larger histogram, the numbers indicate the number of cases in the respective
382 month, and the mean vector (arrow) is the length and direction of the mean date of cases. The
383 smaller histograms represent the best models found, with the average vector (arrow), the
384 density (dashed line), and the average direction (dashed arrows).

385

386 Data Availability

387 The data that support the findings of this study will be made available in the supplementary
388 of this article.

389 Conflicts of Interest

390 The authors declare no conflicts of interest.

391 Authors' Contributions

392 Conceptualization: G.G.C.L, Z.C.F.G, F.G.N, and A.R.M.F; methodology: G.G.C.L, F.G.N,
393 Z.C.F.G, V.A.N, E.F.L, D.M.C.A, and A.R.M.F; investigation: G.G.C.L, Z.C.F.G, V.A.N,
394 D.M.C.A, F.G.N and A.R.M.F; resources: A.R.M.F, Z.C.F.G, C.M.E.C, L.H.F.D and
395 C.C.M.G; data curation: G.G.C.L, V.A.N, E.F.L, F.G.N, D.M.C.A and A.R.M.F; writing –
396 preparation of the original draft: G.G.C.L, A.R.M.F, Z.C.F.G, E.F.L, D.M.C.A, V.A.N, and
397 F.G.N; writing – proofreading and editing: G.G.C.L, Z.C.F.G, A.R.M.F, D.M.C.A, V.A.N,
398 E.F.L, C.M.E.C, L.H.F.D, C.C.M.G and F.G.N; formal analysis: G.G.C.L, Z.C.F.G,
399 A.R.M.F, D.M.C.A, V.A.N and F.G.N; statistical analysis: G.G.C.L and D.M.C.A;
400 supervision: A.R.M.F and Z.C.F.G; financing acquisition: A.R.M.F, Z.C.F.G, C.M.E.C,

401 L.H.F.D and C.C.M.G. All authors read and agreed with the published version of the
402 manuscript.

403 **Funding Statement**

404 This work was supported by the Foundation Oswaldo Cruz: Fiocruz Mato Grosso do Sul,
405 Fiocruz Amazônia and Fiocruz Rio de Janeiro, the Central Public Health Laboratory/Mato
406 Grosso do Sul (LACEN) and the Mato Grosso do Sul State Health Secretaria (SES) and
407 Evandro Chagas institute.

408 **Acknowledgments**

409 The authors would like to thank the Central Public Health Laboratory/Mato Grosso do Sul
410 (LACEN) and the Mato Grosso do Sul State Health Secretaria (SES) for their support in
411 carrying out the analyses. The authors also thank FIOCRUZ/MS, FIOCRUZ/AM,
412 FIOCRUZ/RJ, and Evandro Chagas institute for their support and supply of control samples.

413 **Supplementary Materials**

414 Supplementary 1. Table S1. Primers and probes were used in the study for B19V detection
415 (NAVECA et al., unpublished data).

416 Supplementary 2. Table S2. Components and volumes used to prepare the reactions for B19V
417 detection (NAVECA et al., unpublished data).

418 Supplementary 3. Table S3. Primers and probes are used for amplification of the entire
419 genome of B19V.

420 Supplementary 4. Table S4. Results for 2017 data, with comparison for all 10 orientation
421 models implemented in the R package ‘CircMLE’.

422 Supplementary 5. Table S5. Results for 2018 data, with comparison for all 10 orientation
423 models implemented in the R package ‘CircMLE’.

424 Supplementary 6. Table S6. Results for 2019 data, with comparison for all 10 orientation
425 models implemented in the R package ‘CircMLE’.

426 Supplementary 7. Figure S1. Age group and gender of sampled patients. n, number of
427 patients sampled by age group.

428 Supplementary 8. Figure S2. The B19V samples that underwent sequencing originate from
429 different municipalities in different geographic areas, demonstrating the wide dissemination
430 of the virus throughout the state.

431 **ORCID**

432 Gislene Lichs  <https://orcid.org/0000-0002-0359-4444>

433 Zoraida del Carmen Fernandez <https://orcid.org/0000-0003-2393-946X>

434 Valdinete A Nascimento <https://orcid.org/0000-0002-7786-4718>

435 Daniel Maximo Corrêa Alcantara <https://orcid.org/0000-0002-8333-377X>

436 Everton Lemos <https://orcid.org/0000-0001-6652-9191>

437 Crhistine Carvalho Maymone Gonçalves <https://orcid.org/0000-0001-6953-4965>

438 Cristiano M. Espínola Carvalho <https://orcid.org/0000-0002-3867-9528>

439 Luiz H Demarchi <https://orcid.org/0000-0001-8693-7897>

440 Felipe G Naveca <https://orcid.org/0000-0002-2888-1060>

441 Alexsandra R.M. Favacho <https://orcid.org/0000-0002-4950-2357>

442

443 References

444

- 445 1. YE, C., et al., *Parvovirus-like particles in human sera*. Lancet (London, England),
446 1975. 1(7898).
- 447 2. Moore, T.L.M., *Parvovirus-associated arthritis: Current Opinion in Rheumatology*.
448 2023.
- 449 3. Cotmore, S.F., et al., *The family Parvoviridae*. Archives of Virology, 2013. 159(5): p.
450 1239-1247.
- 451 4. A, S., et al., *Genetic diversity within human erythroviruses: identification of three*
452 *genotypes*. Journal of Virology, 2002. 76(18).
- 453 5. A, d.S.C., et al., *Detection of the human parvovirus B19 in a blood donor plasma in*
454 *Rio de Janeiro*. Memórias do Instituto Oswaldo Cruz, 2023. 84(2): p. 279-280.
- 455 6. Cnc Garcia, R. and L.A. Leon, *Human parvovirus B19: a review of clinical and*
456 *epidemiological aspects in Brazil*. Future Microbiol, 2021. 16(1): p. 37-50.
- 457 7. Alves, A. *Beyond arboviruses: A multicenter study to evaluate the differential*
458 *diagnosis of rash diseases and acute febrile illness cases in Rio de Janeiro, Brazil /*
459 *PLOS ONE*. 2023; Available from:
460 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271758>.
- 461 8. RC, C., et al., *Human parvovirus B19 infections among exanthematic diseases*
462 *notified as measles*. Revista da Sociedade Brasileira de Medicina Tropical, 1997.
463 30(1).
- 464 9. Anisimova, M., et al., *Approximate Likelihood-Ratio Test for Branches: A Fast,*
465 *Accurate, and Powerful Alternative*. Systematic Biology, 2006. 55(4): p. 539-552.
- 466 10. Makowski, *CRAN - Package jtools*. 2023.
- 467 11. Lüdecke, D., et al., *performance: An R Package for Assessment, Comparison and*
468 *Testing of Statistical Models*. Journal of Open Source Software, 2021. 6(60): p. 3139.
- 469 12. Bates, D., et al., *Fitting Linear Mixed-Effects Models using lme4*. 2014.
- 470 13. Team, R.C. *R: The R Project for Statistical Computing*. 2022; Available from:
471 <https://www.r-project.org/>.
- 472 14. Long, *CRAN - Package jtools*. 2023.
- 473 15. Harting, *CRAN - Package DHARMa*. 2023.
- 474 16. Almeida, A., C. Codeço, and P.M. Luz, *Seasonal dynamics of influenza in Brazil: the*
475 *latitude effect*. BMC Infectious Diseases, 2018. 18(1): p. 1-9.
- 476 17. L, L., R. GD, and M. EP, *The Hermans-Rasson test as a powerful alternative to the*
477 *Rayleigh test for circular statistics in biology*. BMC Ecology, 2019. 19(1).
- 478 18. Landler, L., et al., *Model selection versus traditional hypothesis testing in circular*
479 *statistics: a simulation study*. Biology Open, 2020. 9(6).
- 480 19. RR, F. and J. S, *Bringing the analysis of animal orientation data full circle: model-*
481 *based approaches with maximum likelihood*. The Journal of Experimental Biology,
482 2017. 220(Pt 21).
- 483 20. Schnute, J., *Statistical analysis of animal orientation data*. 1992.
- 484 21. Ojeda, V., et al., *Latitude does not influence cavity entrance orientation of South*
485 *American avian excavators*. Ornithology, 2022. 138(1).
- 486 22. Burnham, K.P., D.R. Anderson, and K.P. Huyvaert, *AIC model selection and*

- 487 *multimodel inference in behavioral ecology: some background, observations, and*
488 *comparisons*. Behavioral Ecology and Sociobiology, 2010. 65(1): p. 23-35.
- 489 23. S, P., *A primer on model selection using the Akaike Information Criterion*. Infectious
490 Disease Modelling, 2020. 5.
- 491 24. Agostineli, C. *R-Forge: Circular Statistics: Project Home*. 2023; Available from:
492 <https://r-forge.r-project.org/projects/circular/>.
- 493 25. E, M., et al., *Laboratory assessment and diagnosis of congenital viral infections:*
494 *Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus*
495 *(HSV), parvovirus B19 and human immunodeficiency virus (HIV)*. Reproductive
496 toxicology (Elmsford, N.Y.), 2006. 21(4).
- 497 26. Qiu, J., M. Söderlund-Venermo, and N.S. Young, *Human Parvoviruses*. 2016.
- 498 27. Suzuki, M., et al., *Parvovirus B19 Infection: A Vasculitis Masquerade in an Elderly*
499 *Patient*. American Journal of Case Reports, 2023. 24.
- 500 28. Young, N.S. and K.E. Brown, *Parvovirus B19*. [https://doi.org/10.1056/NEJMra](https://doi.org/10.1056/NEJMra030840)
501 [030840](https://doi.org/10.1056/NEJMra030840), 2004.
- 502 29. T, V.A., et al., [*Incidence and clinical characteristics of maculopapular exanthemas*
503 *of viral etiology*]. Atencion primaria, 2003. 32(9).
- 504 30. Bouraddane, M., K. Warda, and S. Zouhair, *Parvovirus B19, and Pregnant Women: A*
505 *Bibliographic Review*. Open Journal of Obstetrics and Gynecology, 2021. 11(11): p.
506 1543.
- 507 31. SN, S., et al., *Molecular and phylogenetic analyses of human Parvovirus B19 isolated*
508 *from Brazilian patients with sickle cell disease and β -thalassemia major and healthy*
509 *blood donors*. Journal of Medical Virology, 2012. 84(10).
- 510 32. WC, K. and A. SP, *Human parvovirus B19 infections in women of childbearing age*
511 *and within families*. The Pediatric Infectious Disease Journal, 2023. 8(2): p. 83-87.
- 512 33. Toan, N.L., et al., *Phylogenetic analysis of human parvovirus B19, indicating two*
513 *subgroups of genotype 1 in Vietnamese patients*. 2006.
- 514 34. Parsyan, A., et al., *Identification and genetic diversity of two human parvovirus B19*
515 *genotype 3 subtypes*. 2007.
- 516 35. Conteville, L.C., et al., *Parvovirus B19 1A complete genome from a fatal case in*
517 *Brazil*. Memórias do Instituto Oswaldo Cruz, 2023. 110: p. 820-821.
- 518 36. Sanabani, S., et al., *Sequence Variability of Human Erythroviruses Present in Bone*
519 *Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological*
520 *Symptoms*. 2006.
- 521 37. MW, M.-d.B., et al., *Global co-existence of two evolutionary lineages of parvovirus*
522 *B19 1a, different in genome-wide synonymous positions*. PloS One, 2012. 7(8).
- 523 38. Rahiala, J., et al., *Human parvoviruses B19, PARV4 and bocavirus in pediatric*
524 *patients with allogeneic hematopoietic SCT*. Bone Marrow Transplantation, 2013.
525 48(10): p. 1308-1312.
- 526 39. Oliveira, M.I.d., et al., *Genotype 1 of human parvovirus B19 in clinical cases*. Revista
527 da Associação Médica Brasileira, 2017. 63: p. 224-228.
- 528 40. Seetha, D., et al., *Molecular-genetic characterization of human parvovirus B19*
529 *prevalent in Kerala State, India*. Virology Journal, 2021. 18(1): p. 1-8.
- 530 41. M, H., et al., *Parvovirus B19 infection in pediatric allogeneic hematopoietic cell*
531 *transplantation - Single-center experience and review*. Transplant infectious disease:
532 an official journal of the Transplantation Society, 2023. 25(2).
- 533 42. RB, F., et al., *Molecular characterization of human erythrovirus B19 strains obtained*
534 *from patients with several clinical presentations in the Amazon region of Brazil*.
535 Journal of Clinical Virology: the official publication of the Pan American Society for
536 Clinical Virology, 2008. 43(1).

- 537 43. RC, C.G., et al., *Molecular diversity of human parvovirus B19 during two outbreaks*
538 *of erythema infectiosum in Brazil*. The Brazilian journal of infectious diseases: an
539 official publication of the Brazilian Society of Infectious Diseases, 2017. 21(1).
- 540 44. Hicks, K.E., et al., *Sequence analysis of a parvovirus B19 isolate and baculovirus*
541 *expression of the non-structural protein*. Archives of Virology, 2023. 141(7): p. 1319-
542 1327.
- 543 45. Cubel, R.C.N., et al., *Human parvovirus B19 infections among exanthematic diseases*
544 *notified as measles*. Revista da Sociedade Brasileira de Medicina Tropical, 1997. 30:
545 p. 15-20.
- 546 46. Oliveira, M.I.d., et al., *Genotype 1 of human parvovirus B19 in clinical cases*. Revista
547 da Associação Médica Brasileira, 2023. 63: p. 224-228.
- 548 47. Garcia, R.d.C. and L.A. Leon, *Human parvovirus B19: a review of clinical and*
549 *epidemiological aspects in Brazil*. <https://doi.org/10.2217/fmb-2020-0123>, 2021.
- 550 48. Freitas, R.B.d., et al., *Parvovirus B19 antibodies in sera of patients with unexplained*
551 *exanthemata from Belém, Pará, Brazil*. 1993.

Supplementary Material

Erythrovirus B19 (B19V) in patients with acute febrile illness suspected of arboviruses in Mato Grosso do Sul, Brazil

Table S1. Primers and probes used in the study for B19V detection (NAVECA et al., unpublished data).

Oligonucleotides	Sequence
B19_FNF	5' ACAAGCCTGGGCAAGTTAGC 3'
B19_FNR	5' CATTRCCAGGCCCAACAT 3'
B19_FN_P	5' (FAM) TACAAC TACCCGGTACTAAC 3'

Table S2. Components and volumes used to prepare the reactions for B19V detection (NAVECA et al., unpublished data).

Component	10 µl reaction
Nuclease-free water	1.4 µL
2X PCR Master Mix Kapa Probe	5 µL
Primer mix (5 µM)	0.6 µL
Probe (10µM) FAM	0.1 µL
Rox Dye	0.4 µL
Template DNA	2.5 µL

Table S3. Primers and probes used for amplification of the entire genome of B19V.

Name	Sequence 5'- 3'	Length (bp)
B19V_350FNF (forward)	CGGCATCTGATTTGGTGTCTTC	2037
B19V_2387FNR (reverse)	CACACATAATCAACCCCAACTAACA	
B19V_1605FNF (forward)	AAGTACAGGAAAAACAACTTGGCAA	2258
B19V_3862FNR (reverse)	GTAAGCATATTGAGGGGGAAAGTATAC	
B19V_3298FNF (forward)	CCCAAGCATGACTTCAGTTAATTCT	1679
B19V_4976FNR (reverse)	GGAGTGTTTACAATGGGTGCAC	

Table S4. Results for 2017 data, with comparison for all 10 orientation models implemented in the R package ‘CircMLE’. The models are described by five parameters: the mean direction (ϕ_1 , in degrees) and concentration parameter (k_1) for the first mode, the mean direction (ϕ_2 , in degrees) and concentration parameter (k_2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc w_i , model weights; ER, evidence ratio.

Modelo	ϕ_1	k_1	λ	ϕ_2	k_2	AICc	ΔAICc	AICc w_i	ER
M3A	4.40	3.18	0.50	7.54	3.18	59.11	0.00	0.38	-
M4A	4.39	3.20	0.65	7.53	3.20	60.68	1.58	0.17	2.20
M2C	4.66	49.99	0.25	-	0.00	61.27	2.17	0.13	2.96
M2B	4.50	5.80	0.50	-	0.00	61.60	2.50	0.11	3.49
M3B	4.45	4.05	0.50	7.59	1.64	61.81	2.70	0.10	3.86
M1	-	0.00	1.00	-	0.00	62.49	3.38	0.07	5.43
M4B	1.25	3.02	0.36	4.39	3.29	64.16	5.06	0.03	12.53
M2A	4.25	0.51	1.00	-	0.00	65.23	6.13	0.02	21.40
M5B	4.36	3.31	0.64	1.31	3.02	68.20	9.10	0.00	94.38
M5A	3.45	5.00	0.41	2.66	5.00	2000000011.33	1999999952.23	0.00	-

Table S5. Results for 2018 data, with comparison for all 10 orientation models implemented in the R package ‘CircMLE’. The models are described by five parameters: the mean direction (ϕ_1 , in degrees) and concentration parameter (k_1) for the first mode, the mean direction (ϕ_2 , in degrees) and concentration parameter (k_2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc w_i , model weights; ER, evidence ratio.

Modelo	ϕ_1	k_1	λ	ϕ_2	k_2	AICc	ΔAICc	AICc w_i	ER
M5A	5.08	4.62	0.47	2.49	4.62	71.17	0.00	0.38	-
M3A	5.37	3.63	0.50	8.51	3.63	71.44	0.27	0.33	1.15
M4A	2.23	3.64	0.54	5.37	3.64	74.04	2.87	0.09	4.20
M3B	2.26	4.48	0.50	5.40	2.84	74.05	2.88	0.09	4.22
M5B	2.49	4.49	0.54	5.09	4.82	74.56	3.39	0.07	5.45
M4B	2.25	4.10	0.53	5.39	3.15	77.03	5.86	0.02	18.73
M2C	2.12	30.86	0.25	-	0.00	79.63	8.46	0.01	68.53
M2B	2.26	16.46	0.50	-	0.00	80.36	9.19	0.00	98.94
M1	-	0.00	1.00	-	0.00	80.87	9.70	0.00	127.51
M2A	3.55	0.51	1.00	-	0.00	82.80	11.63	0.00	335.68

Table S6. Results for 2019 data, with comparison for all 10 orientation models implemented in the R package ‘CircMLE’. The models are described by five parameters: the mean direction (ϕ_1 , in degrees) and concentration parameter (k_1) for the first mode, the mean direction (ϕ_2 , in degrees) and concentration parameter (k_2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc w_i , model weights; ER, evidence ratio.

Modelo	ϕ_1	k_1	λ	ϕ_2	k_2	AICc	ΔAICc	AICc w_i	ER
M2A	1.31	1.46	1.00	-	0.00	77.34	0.00	0.72	-
M5A	0.33	2.58	0.37	1.82	2.58	81.43	4.09	0.09	7.73
M2C	1.33	2.15	0.75	-	0.00	81.65	4.32	0.08	8.66
M2B	1.39	2.36	0.50	-	0.00	82.11	4.78	0.07	10.89
M3B	4.62	0.00	0.50	7.76	2.24	84.84	7.51	0.02	42.64
M4B	4.40	0.00	0.27	7.54	2.30	85.00	7.67	0.02	46.20
M5B	6.28	2.53	0.49	1.71	3.82	88.08	10.74	0.00	215.33
M1	-	0.00	1.00	-	0.00	91.89	14.56	0.00	1450.15
M3A	1.52	0.98	0.50	4.66	0.98	95.82	18.48	0.00	10315.06
M4A	5.56	0.81	0.25	8.70	0.81	96.28	18.95	0.00	13008.91

Figure S1. Age group and gender of sampled patients. n, number of patients sampled by age group.




Figure S2. The B19V samples that underwent sequencing originate from different municipalities in different geographic areas, demonstrating the wide dissemination of the virus throughout the state.

